Saturday 17 October 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022. In the quarter to June 2026, EPS grew 26.5% and free cash flow fell 50.1%, each against the same quarter a year earlier.

79.90 0.20 −0.25%

Follow SYRE

Alert me

Market cap: $7.4B
P/E: 0.0×
Fwd P/E: −4.8×
Dividend yield: —
F-score: 3/9
Altman Z: −3.82
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 442.98

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	1	1	2	3	4	6	3	3	4	2

Insider Ownership 2.37%

Capital & Financial Ratios $m

Market Cap 7,390.00

Revenue 1.05

Net Income (178.92)

Free Cash Flow (208.94)

Net Debt (1,145.35)

Current Ratio 18.53

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (4.84)

P/S ratio 6,423.00

P/B ratio 7.09

Past 5Y EPS Growth —

This Y EPS Growth (37.52%)

Next Y EPS Growth (32.04%)

Next Y revenue growth 162.08%

Next 5Y EPS Growth (28.16%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 96.90%

10-year low 10-year high

P/B against its own 10 years 91.36%

10-year low 10-year high

EV/Sales against its own 10 years 95.76%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	339	603	757	1,145
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	342	608	778	1,173

	2023	2024	2025	Q'26
Payables	1	1	9	6
ST’ Debt	—	—	—	—
Other	1	25	23	31
	32	54	59	63

Compound Annual Growth %

	10y	5y	3y
Sales	—	(28.15%)	(38.92%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	34.80%	38.60%	142.26%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’23	0	1	—	0	1
’22	1	1	0	0	2
’21	—	14	1	4	19
’18	2	2	—	—	4
’17	1	1	1	1	5

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(57)	(70)	—	—	—
’25	(41)	(47)	(37)	(45)	(169)
’24	(29)	(62)	(29)	(37)	(157)
’23	(18)	(17)	(35)	(31)	(100)
’22	(26)	(21)	(15)	(18)	(80)
’21	(20)	2	(17)	(19)	(54)
’20	(22)	(19)	(18)	(17)	(76)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(57)	(70)	—	—	—
’25	(41)	(47)	(37)	(45)	(169)
’24	(29)	(62)	(29)	(37)	(157)
’23	(18)	(16)	(35)	(31)	(99)
’22	(26)	(21)	(15)	(18)	(80)
’21	(20)	2	(17)	(19)	(54)
’20	(23)	(21)	(18)	(18)	(80)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.74)	(0.36)	—	—	—
’25	(0.74)	(0.49)	(0.15)	(0.89)	(1.98)
’24	(1.20)	(0.86)	(1.36)	(1.01)	(4.42)
’23	(5.00)	(56.75)	(9.34)	(4.05)	(49.12)
’22	(9.25)	(6.75)	(4.75)	(4.50)	(24.75)
’21	(7.00)	(2.50)	(7.75)	(7.75)	(25.00)
’20	(14.25)	(10.00)	(7.25)	(8.50)	(38.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	97.25	70.25	123.75	149.75	87.50	86.75	8.50	2.65	18.54	10.91	Analyst estimates 2026–2028 Powerpack
	High	318.75	203.50	300.00	236.25	284.50	219.75	120.75	24.00	47.97	35.31
People
People	Employees	30	43	61	76	90	101	69	30	65	102
	Revenue/emp, $m	0.15	0.12	0.06	0.00	0.00	0.19	0.03	0.03	0.00	0.00
Income, $m
Income, $m	Revenue	5	5	4	—	—	19	2	1	—	—
	Gross margin, %	100.00	100.00	100.00	0.00	0.00	100.00	100.00	100.00	—	—
	EBT	(22)	(27)	(44)	(78)	(81)	(66)	(84)	(339)	(208)	(155)
	EBT margin, %	(468.84)	(523.27)	(1,140.64)	0.00	0.00	(350.39)	(3,604.59)	(38,241.08)	0.00	0.00
	Net income	(22)	(27)	(44)	(78)	(81)	(66)	(84)	(339)	(208)	(155)
	Depreciation	0	0	0	0	1	3	2	1	(11)	—
Per share, $
Per share, $	Revenue	11.82	8.60	4.67	0.00	0.00	7.13	0.69	0.13	0.00	0.00
	Earnings	(55.50)	(45.00)	(53.25)	(61.25)	(38.00)	(25.00)	(24.75)	(49.12)	(4.42)	(1.98)
	Cash flow	(48.10)	(40.68)	(38.65)	(51.40)	(35.49)	(20.43)	(23.77)	(14.49)	(3.35)	(2.64)
	Capex	(0.54)	(1.02)	(0.51)	(1.17)	(2.00)	(0.22)	(0.01)	0.07	0.00	0.00
	Free cash flow	(48.64)	(41.70)	(39.16)	(52.57)	(37.50)	(20.64)	(23.79)	(14.42)	(3.35)	(2.64)
	Book value	160.75	83.19	80.96	47.01	65.50	31.92	14.92	26.68	11.01	11.17
	Shares, m	0	1	1	1	2	3	3	7	47	64
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	—	—	0.00	0.00	0.00	—	—
	P/S	9.67	15.64	23.52	—	—	14.79	15.24	140.04	—	—
	P/B	0.71	1.62	2.31	—	—	3.72	0.71	0.00	—	—
	EV/Sales	(4.05)	5.97	12.28	—	—	10.38	(8.68)	(181.86)	—	—
	EV/FCF	0.98	(1.23)	(2.50)	—	—	(4.04)	0.25	1.93	—	—
Cash, $m
Cash, $m	Operating cash flow	(19)	(25)	(32)	(66)	(76)	(54)	(80)	(100)	(157)	(169)
	Capex	0	(1)	0	(1)	(4)	(1)	0	0	—	—
	Free cash flow	(19)	(25)	(33)	(67)	(80)	(54)	(80)	(99)	(157)	(169)
Balance, $m
Balance, $m	Working capital	62	49	66	56	133	79	48	310	554	719
	Total debt	—	—	—	5	6	5	5	—	—	—
	Net debt	(64)	(50)	(75)	(72)	(146)	(93)	(56)	(339)	(603)	(757)
	Shareholders’ equity	63	50	67	60	140	84	50	184	518	715
Returns, %
Returns, %	ROA	(41.05)	(44.24)	(66.28)	(97.26)	(66.09)	(48.46)	(92.58)	(164.06)	(43.78)	(22.39)
	ROIC	0.00	(45,519.74)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(106.47)	(48.08)	(75.32)	(122.74)	(80.93)	(58.81)	(124.87)	(1,371.79)	(115.22)	(33.69)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Dec 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PTGX Protagonist Therapeutics, Inc.	$8.8B	106×	25.0×	+3,749.17% (above 0%: growing)	n/m	+839.65% (above 0%: growing)	100.00%	74.37%	Compare
TGTX TG Therapeutics, Inc.	$8.6B	17.8×	29.4×	+70.27% (above 0%: growing)	−73.68% (below 0%: shrinking)	+427.05% (above 0%: growing)	82.86%	9.02%	Compare
AXSM Axsome Therapeutics, Inc.	$8.5B	— (loss-making)	— (loss-making)	+45.54% (above 0%: growing)	n/m	−2.98% (below 0%: shrinking)	93.79%	(22.73%)	Compare
ARWR Arrowhead Pharmaceuticals, Inc.	$8.3B	— (loss-making)	— (loss-making)	+171.02% (above 0%: growing)	n/m	−15.43% (below 0%: shrinking)	100.00%	(226.03%)	Compare
ABVX Abivax SA Sponsored ADR	$8.1B	— (loss-making)	—	—	n/m	−48.28% (below 0%: shrinking)	0.00%	0.00%	Compare
SYRE Spyre Therapeutics, Inc.	$7.4B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−50.07% (below 0%: shrinking)	0.00%	0.00%
IONS Ionis Pharmaceuticals, Inc.	$7.3B	— (loss-making)	— (loss-making)	−40.73% (below 0%: shrinking)	n/m	+299.29% (above 0%: growing)	98.98%	(38.18%)	Compare
PRAX Praxis Precision Medicines, Inc.	$6.9B	— (loss-making)	— (loss-making)	+1,349.13% (above 0%: growing)	n/m	−43.54% (below 0%: shrinking)	100.00%	0.00%	Compare
IOVA Iovance Biotherapeutics, Inc.	$6.7B	— (loss-making)	— (loss-making)	+65.65% (above 0%: growing)	n/m	+11.52% (above 0%: growing)	56.10%	(52.26%)	Compare
Median of peers	$8.2B	—	—	+70.27%	—	+4.27%	96.39%	(11.36%)

All 614 Biotechnology stocks →

Spyre Therapeutics, Inc. (SYRE) key facts

Concern: Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
Spyre Therapeutics, Inc. (SYRE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SYRE traded at $79.90, a market capitalization of $7.4 billion.
Return on equity was −33.7% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −3.82 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.